Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to ...

MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key ...

“Monte Rosa has built one of the largest and highly focused libraries of small molecule protein degraders that target critical disease drivers,” said Dr. Mayweg, Chair of the Board of Directors.

Part three of the trial will involve patients at higher risk of cardiovascular disease due to obesity and elevated CRP levels.

Monte Rosa to receive up-front payment of $150 million and is eligible to receive milestone payments, U.S. profit and loss share, and tiered royalties on ex-U.S. net sales ...

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of ...

Monte Rosa was launched from Ridgeline, Versant’s Discovery Engine based in the Basel Technology Park. The company is now headquartered in Boston, MA, with research operations in both Boston and ...

Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies, and tiered royalties on ex-U.S. net sales.

Monte Rosa's CEO, Markus Warmuth, expressed enthusiasm about Dr. Hughes joining the board, highlighting his expertise in R&D and drug development, which will be invaluable as the company expands ...

Monte Rosa will also be eligible for future payments of up to $2.1 billion as well as royalties on net sales outside the U.S.

Grammy-winning Draco Rosa, who co-created hits like 'Livin' la Vida Loca' while making his mark as a rocker, survived cancer, twice. His new album, 'Monte Sagrado,' takes stock, and celebrates life.

Boston-based Monte Rosa said Thursday that it had raised a Series B round of $96 million. Aisling Capital led the round, while founding investor Versant Ventures participated, along with New ...